Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-03-25
2008-03-25
Blanchard, David J. (Department: 1643)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C530S387100, C424S130100
Reexamination Certificate
active
07348419
ABSTRACT:
A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.
REFERENCES:
patent: 4624846 (1986-11-01), Goldenberg et al.
patent: 4818709 (1989-04-01), Primus et al.
patent: 5443953 (1995-08-01), Hansen et al.
patent: WO 91/11465 (1991-08-01), None
patent: WO 94/04702 (1994-03-01), None
patent: WO 96/01126 (1996-01-01), None
patent: WO 96/11013 (1996-04-01), None
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Genes IV (Lewin et al, Oxford University Press, p. 810, 1990).
Mountain e al., “Engineering Antibodies for Therapy”, Biotechnology and Engineering Reviews, Intercept Ltd., Dec. 1992, p. 1-142, vol. 10.
Graziano et al., “Construction and Characterization of Humanized Anti-y-lg Receptor type I (FcyRl) Monoclonal Antibody”, The Journal of Immunology, The American Association of Immunologists, pp. 4996-5002, Nov. 1995.
Leung et al., “Humanization of an Anti-carcinoembryonic Antigen Anti-idiotype Antibody as a Tumor Vaccine and for Targeting Applications”, Proceedings of the American Association for Cancer Research Annual Meeting, vol. 37, Mar. 1996, Meeting Info.: 87th Annual Meeting of the American Association for Cancer Research, Washington, D.C., USA; Apr. 20-24, 1996.
Losman et al., “Generation and Monitoring of Cell Lines Producing Humanized Antibodies”, Clinical Cancer Research, pp. 3101s-3105s, Oct. 1999, vol. 5.
Losman, et al., Int. J. Cancer, 56-580-584, 1994.
Primus, et al., Cancer Research, 43:686, 1983.
Jones et al., Nature, 332:323, 1988.
Riechmann et al., Nature, 332: 323-327, 1988.
Irvine et al., Cancer Immunology Immunotherapy, 36:281-292, 1993.
Pimm et al., Life Sciences, 56(17); 1401-1406, 1995.
Gaida et al., Intl. J. Cancer, 51:459-465, 1992.
Morrison et al., Hospital Practice, pp. 65-69, 72-74, 77-78, 80, Oct. 15, 1989.
Evan et al., Q J Med. 92-299-307, 1999.
Jain, Cancer and Metastasis Reviews, 9:253-266, 1990.
Seaver, Genetic Engineering News, 14(14):10 and 21, Aug. 1994.
Reiger et al., Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.
Michele J. Losman et al., “Mimicry of a Carcinoembryonic Antigen Epitope by a Rat Monoclonal Anti-Idiotype Antibody”, Int. J. Cancer, 1994, pp. 580-584, vol. 56.
Bhattacharya, Chatterjee M., et al., “Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen,” J. Immunol, Oct. 15, 1990, 145(8):2758-65.
Chakraborty, M., et al., “Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen,” J. Immunother Emphasis Tumor Immunol. Aug. 18, 1995 (2):95:103.
Durrant, L.G., et al., “An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours,” Int. J. Cancer, Mar. 12, 1992 (5):811-6.
Hansen Hans
Leung Shui-on
Losman Michele J.
Blanchard David J.
Faegre & Benson LLP
Immunomedics Inc.
Tungaturthi Parithosh K.
LandOfFree
Humanization of an anti-carcinoembryonic antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanization of an anti-carcinoembryonic antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanization of an anti-carcinoembryonic antigen... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3969759